PDE5A and Alzheimer disease: It would also be interesting to examine whether strategies to chronically augment eNOS/NO (e.g., PDE5 inhibitor, NO donor, l-arginine, regular aerobic exercise [32, 92]), if begun early in AD, inhibit collateral rarefaction.